Voyager nabs $25M cash as Novartis runs with two AAV capsids for neuro gene therapy
After spending a year looking at Voyager’s next-gen AAV capsids, Novartis has picked two of them to be the delivery vector for its gene therapy programs targeting two neurologic diseases.
The license triggers a $25 million payment — $12.5 million for each target — and opens up a road to $600 million in total milestones. But it also leaves some money off the table as Novartis, which had the option to license capsids against a total of three targets, decided not to act on the third.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.